Stoke Therapeutics Inc (STOK)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Stoke Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 8 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 28.90 $ — 63% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 58.5% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 10
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -3.29 | -3.79 – -3.07 | 24 | -2,641.7% | 11 |
| 12/31/2027 | -3.09 | -3.67 – -2.05 | 47 | 6.1% | 10 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.82 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.18 | – | 23 | 707.10 | -46.40 | -23 | -23 |
| 2025: Q1 | 1.90 | – | 159 | 3,661.10 | 71.20 | 132 | 132 |
| 2025: Q2 | -0.40 | – | 14 | 186.00 | -170.00 | -25 | -26 |
| 2025: Q3 | -0.65 | – | 11 | 117.20 | -360.70 | -30 | -31 |
| 2025: Q4 | -0.99 | – | 1 | -93.80 | -4,132.20 | -31 | -31 |
| 2026: Q1 | -0.79 | -141.70 | 6 | -96.10 | -802.70 | -61 | -61 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 0 | -6 | -6 | -0.24 | -5 | -1 | 2 |
| 2018 | 0 | -13 | -13 | -0.53 | -11 | 105 | 108 |
| 2019 | 0 | -36 | -29 | -1.59 | -31 | 224 | 229 |
| 2020 | 0 | -53 | -51 | -1.51 | -42 | 286 | 298 |
| 2021 | 3 | -86 | -85 | -2.31 | -67 | 218 | 239 |
| 2022 | 12 | -104 | -93 | -2.39 | -32 | 185 | 256 |
| 2023 | 9 | -115 | -105 | -2.38 | -81 | 160 | 228 |
| 2024 | 37 | -101 | -89 | -1.65 | -87 | 229 | 272 |
| 2025 | 184 | -21 | -7 | -0.12 | 46 | 352 | 418 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Stoke Therapeutics, Inc. befasst sich mit der Entwicklung von Behandlungen für schwere genetische Erkrankungen durch Hochregulierung der Proteinexpression.
| Employees | 170 |
|---|---|
| Headquarters | Bedford, MA |
| Address | 45 Wiggins Avenue, 01730 Bedford, United States |
| Phone | 781 430 8200 |
| Website | stoketherapeutics.com |
| IPO Date | 19. Jun 2019 |
| ISIN | US86150R1077 |
| Stock Split | 1:9 on 06/06/2019 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Ian F. Smith A.C.A., C.P.A. | CEO & Director | 1966 |
| Adrian R. Krainer Ph.D. | Co-Founder & Independent Director | 1959 |
| Thomas Edward Leggett | Chief Financial Officer | 1977 |
| Edward M. Kaye M.D., Ph.D. | Advisor & Director | 1949 |
| Jason Hoitt | Chief Patient Officer | 1978 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.